Plate Nº 38 · recorded September 29, 2026
Neuroscience & MindReported finding
Early Statin Use After Diabetes Diagnosis Linked to Lower Dementia Risk
Danish researchers followed 132,585 people with new type 2 diabetes diagnoses and found that starting statins within a year was linked to a 15% lower relative dementia risk over 10 years.
By Elena Vasquez4 min read828 words
In brief
- In a Danish nationwide study of 132,585 people with new type 2 diabetes, starting statins within one year of diagnosis was associated with a 15% lower relative risk of dementia over 10 years.
- Starting statins between one and five years after diagnosis was linked to a smaller, 10% lower relative risk; 2.7% of participants developed dementia during a median follow-up of 7.1 years.
- The study was observational and cannot prove statins prevent dementia, though it used trial-emulating methods to reduce bias; results were similar in women and men.
People with type 2 diabetes who started statin treatment within a year of their diagnosis had a 15% lower relative risk of developing dementia over 10 years, according to a large Danish study presented at ESC Congress 2026 and published in The Lancet Regional Health – Europe.
The study tracked 132,585 people who had never taken statins before receiving a type 2 diabetes diagnosis between 2006 and 2019. Those who delayed the drugs also benefited, but less: starting statins between one and five years after diagnosis came with a 10% lower relative risk of dementia over the same period. Results were similar in women and men.
Why researchers looked at this question
As populations age, dementia cases are expected to rise substantially. No effective treatment currently exists that can prevent or reverse most forms of the condition, so researchers are increasingly searching for factors that reduce the likelihood of developing it.
The Lancet Commission estimates that nearly half of dementia cases could theoretically be prevented by addressing 14 modifiable risk factors. One of those factors involves managing cholesterol starting in midlife.
"Detecting and treating high levels of low-density lipoprotein cholesterol (LDL-C) from midlife is one such highlighted risk factor," explained Dr. Tummas Ternhamar of Copenhagen University Hospital, Denmark, who presented the findings. LDL-C is often called "bad" cholesterol because it can build up in artery walls.
The question is especially relevant for people with type 2 diabetes. High LDL-C is common in these patients, and diabetes itself is already recognized as a risk factor for cognitive decline and dementia.
"We hypothesized that early initiation of LDL-C-lowering statins following type 2 diabetes diagnosis could be associated with a lower risk of dementia," said Dr. Ternhamar. "And we tested this in a large nationwide study using analysis methods to emulate a randomized trial and reduce some of the bias associated with observational studies."
How the study worked
The researchers used Danish national registers to identify people who developed type 2 diabetes between 2006 and 2019 and had not previously taken statins. They followed participants through the end of 2021 and searched medical records for diagnoses of all-cause dementia — meaning dementia from any cause, not just Alzheimer's disease.
To compare timing of treatment, the team used a statistical technique called a clone-censor-weight design. In plain terms, this method mimics a randomized trial by mathematically balancing the comparison groups, which helps reduce some of the bias that plagues ordinary observational studies.
The researchers split participants into three groups: those who did not start statins within five years of diagnosis, those who started within one year, and those who started between one and five years later.
During a median follow-up of 7.1 years, 2.7% of participants developed dementia.
What the numbers mean — and what they don't
The findings point to a potential brain benefit from starting statins promptly, on top of the drugs' established role in protecting against heart attack and stroke. Timing appears to matter: the earlier treatment began, the stronger the association with reduced dementia risk.
But an important caveat applies. Because the study was observational, it cannot prove that statins directly prevent dementia. People who start statins early may differ from those who don't in ways the analysis could not fully capture — for example, in how closely they follow medical advice overall.
Professor Isabel Goncalves, a member of the ESC Communication Committee, put the results in perspective: "People with type 2 diabetes already have a higher risk of dementia and are advised to lower cholesterol to reduce their risk of heart attack and stroke. This study suggests that starting statins soon after a type 2 diabetes diagnosis may also be linked to a modest reduction in dementia risk, with greater benefit than delaying treatment."
"Because statins are widely available and inexpensive, the findings are potentially important," she added. "However, this was an observational study, so it cannot prove that statins prevent dementia. The results should therefore support further research and help inform discussions between patients and clinicians."
Underuse despite known benefits
Dr. Ternhamar highlighted a practical concern: statins appear to be underused in patients with type 2 diabetes, despite their proven protective effects against cardiovascular disease.
"In individuals developing type 2 diabetes, statins were associated with a lower risk of dementia, most pronounced in those with early initiation," he concluded. "Our findings suggest another potentially important reason to ensure that patients with type 2 diabetes and high LDL-C receive timely statin treatment."
The bottom line for patients: the study adds a possible, still unproven, brain-related reason to follow existing guidance on cholesterol management after a diabetes diagnosis. Anyone with questions about statin timing should discuss their individual risk profile with their clinician.
The work was supported by grants from the Danish Cardiovascular Academy (funded by the Novo Nordisk Foundation and The Danish Heart Foundation), Herlev and Gentofte Hospital, and several private Danish foundations.
via ScienceDaily: Mind & Brain (Source)
More from Elena Vasquez
Nearby plates
- Anti-Aging Drug Boosts Brain Blood Flow in People at Higher Alzheimer's Risk
- Bodies Show Decline Years Before Heart Attacks and Strokes Strike
- New Roadmap Aims to Make Brain Resilience Research More Inclusive
- Diet and Exercise Reverse Early-Onset Type 2 Diabetes in Half of Cases
- UK Launches £80m Challenge to Speed Up Dementia Diagnosis